For following the competition: what moved in each program, several studies read as one move.
- elebsiran
- tobevibart
- Anti-EGFR/CD3 Protease-activated T-cell Engager VIR-5525
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Vir Biotechnology to watchlistEvery Monday by email · turn it off any timePro · free during the beta